Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Gap Up – What’s Next?

Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY)’s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $20.75, but opened at $21.7899. Chugai Pharmaceutical shares last traded at $20.8345, with a volume of 12,930 shares trading hands.

Analyst Upgrades and Downgrades

Several equities analysts recently weighed in on the company. Nomura upgraded Chugai Pharmaceutical to a “hold” rating in a research note on Tuesday, September 1st. The Goldman Sachs Group upgraded Chugai Pharmaceutical from a “hold” rating to a “buy” rating in a research report on Monday, June 15th. Zacks Research upgraded Chugai Pharmaceutical to a “hold” rating in a research report on Friday, May 29th. Finally, UBS Group cut Chugai Pharmaceutical from a “strong-buy” rating to a “hold” rating in a research report on Thursday, August 6th. One research analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy”.

Chugai Pharmaceutical Stock Up 0.5%

The company’s 50-day moving average price is $21.83 and its 200-day moving average price is $24.67. The firm has a market cap of $68.61 billion, a price-to-earnings ratio of 22.66 and a beta of 0.59.

Chugai Pharmaceutical (OTCMKTS:CHGCY) last issued its quarterly earnings results on Friday, July 24th. The company reported $0.22 earnings per share for the quarter. Chugai Pharmaceutical had a net margin of 35.09% and a return on equity of 23.76%. The firm had revenue of $2.14 billion for the quarter, compared to analyst estimates of $2.38 billion. Analysts predict that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.96 earnings per share for the current fiscal year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs.

Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer.